Group Leader PKPD, Principal Scientist II
Curtis joined Metrum in 2014 after receiving his Pharm.D. from the University at Buffalo and completing a clinical PK/PD Fellowship through UNC Chapel Hill/Quintiles. His clinical experience includes infectious disease (bacterial), oncology, and chronic liver disease (HCV and NASH). Curtis’s research interests include Bayesian methodology and the application of M&S to help inform drug development decisions.
July 8, 2024
Presented at PAGE 2024. The bbr.bayes package reduces much of the friction associated with a Bayesian pharmacometrics analysis in NONMEM® and promotes good practice applications.
December 11, 2023
In this tutorial, the principles of Bayesian model development, assessment and prior selection are outlined. An example pharmacokinetic model is used to demonstrate the implementation of Bayesian modeling using the nonlinear mixed-effects modeling software NONMEM.
November 15, 2023
Presented at ACoP14. Empagliflozin, effective for type 2 diabetes in adults and children, underwent Study 1218.91 to assess its safety and efficacy over 26 weeks (with potential extension to 52 weeks) in children and adolescents. Using pediatric data from this study, researchers re-evaluated empagliflozin’s models in a Bayesian framework. Results showed similar drug exposure between children and adults at a 10 mg dose. At week 26, pediatric patients displayed a slightly larger but variable decrease in A1c compared to adults. This Bayesian method allowed insights into empagliflozin’s effects in children, drawing from knowledge gained in adult studies.